A phase Ib study of NUC-3373 in combination with standard therapies in advanced/metastatic colorectal cancer (NuTide:302).
Andrew L. Coveler(University of Washington), T.R. Jeffry Evans(Leiden University Medical Center), Kristen K. Ciombor(The Ohio State University), Michelle Myers(Nucana (United Kingdom)), Jordan Berlin(Dana-Farber Cancer Institute), Sarah P. Blagden(Churchill Hospital), Farasat Kazmi(University of Oxford), Janet Graham(Beatson West of Scotland Cancer Centre), Lisa Rodgers(Beatson West of Scotland Cancer Centre)
Cited by 6
Related Papers
Phase 3 Trial of <sup>177</sup> Lu-Dotatate for Midgut Neuroendocrine Tumors
|New England Journal of Medicine|2017|3.2k
Rethinking ovarian cancer II: reducing mortality from high-grade serous ovarian cancer
|Nature reviews. Cancer|2015|1.4k